Vitek ms maldi tof system

The culture-based screening method was chosen by expert consensus. We collected samples within 24 hours of admission to ICU at the same time as other routine screening samples. We collected swabs from: (i) nose; (ii) throat; (iii) axilla; (iv) groin; (v) perineum; (vi) rectum; and (vii) a catheter urine sample. Swabs were transported to the clinical laboratory in standard tubes without viral transport media or any solution with antifungal activity. All except one laboratory were on the participating hospital sites. Laboratory diagnosis was undertaken based on an agreed standard operating procedure. Swabs and urine were directly streaked onto Sabouraud Dextrose agar plates (SDA) (or CHROMagar followed by sub-culture on SDA) and incubated aerobically at 37 °C for 7 days, checking for yeast growth every 24 hours. Morphologically distinct colonies were sub-cultured before identification or were directly identified using MALDI-TOF MS. Six of the seven laboratories (one laboratory served two ICUs) used the Bruker MALDI-TOF MS system (Bruker, Karlsruhe, Germany) and one used the VITEK MALDI-TOF MS system (bioMerieux, Craponne, France). We collected data on the laboratory results for each body site tested, along with patient identifiers.

Five-hundred and twelve yeasts isolates were collected from blood cultures from 2011 to 2014 at the National Cheng Kung University Hospital, a medical center in southern Taiwan. All blood samples were incubated in BACTEC FX (Becton, Dickinson and Company, Sparks, MD, United States), and the laboratory yeast isolates were identified by the VITEK Yeast Biochemical Card (YBC) before 2012 and VITEK 2 YST ID Card (bioMérieux, Inc., Hazelwood, MO, United States) after 2012. Morphological identification and germ tube tests were also used when necessary. Pure colonies of those isolates were further analyzed by the commercial VITEK MALDI-TOF MS system (bioMérieux; hereinafter named VITEK MS) and oligonucleotide arrays.

Clinical isolates of Elizabethkingia species, obtained between 2005 and 2020, were collected from 5 hospitals in Taiwan, namely, E-Da Hospital, Kaohsiung Medical University Hospital, E-Da Cancer Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital. These isolates had been routinely collected from patients in accordance with clinical requirements. All isolates were initially identified as Elizabethkingia species by clinical microbiology laboratories using API/ID32 phenotyping kits (bioMérieux, Marcy l’Etoile, France), the Phoenix 100 ID/AST automated microbiology system (Becton, Dickinson Co., Sparks, MD, USA), the Vitek 2 automated identification system (bioMérieux), or the Vitek MALDI-TOF MS system (bioMérieux). Isolates were stored as glycerol stocks at −80°C until use.